Step 1 topics → General Pathology → Paraneoplastic Syndromes

Paraneoplastic Syndromes

USMLE Step 1 trap: Misattributes PTHrP-mediated hypercalcemia to small cell lung cancer instead of squamous cell lung cancer. Small cell lung cancer causes SIADH (via ADH) and ectopic ACTH (Cushing syndrome), while squamous cell lung cancer causes hypercalcemia via PTHrP.

Paraneoplastic syndromes are effects of malignancy that aren't caused by direct tumor invasion or metastasis — instead, they're driven by tumor-secreted hormones, peptides, or immune cross-reactivity. The concept sounds straightforward, but USMLE Step 1 loves to test it in ways that expose sloppy pattern-matching. The most common trap: students memorize 'small cell lung cancer = paraneoplastic' without tracking which syndromes go with which histologic subtype. That single gap accounts for a huge chunk of wrong answers on these questions.

Step 1 tests paraneoplastic syndromes from multiple angles. Pure recall questions ask you to match a syndrome to its tumor source (Lambert-Eaton → small cell). Application questions give you lab values — low sodium, high cortisol, elevated calcium — and ask you to identify the underlying mechanism and most likely tumor. Passage-based questions often bury the paraneoplastic clue inside a clinical vignette, expecting you to recognize that a patient's hypercalcemia isn't from bone mets but from PTHrP secretion by a squamous cell lung carcinoma, or that a patient's polycythemia is from EPO production by a renal cell carcinoma. The exam rewards students who know the mechanism, not just the association.

The trickiest part is malignancy-associated hypercalcemia — students default to PTHrP for everything, but there are three distinct mechanisms (PTHrP from solid tumors, osteolytic mets, ectopic calcitriol from lymphomas) and the exam distinguishes them. Cancer cachexia is another underappreciated test point: most students explain it as 'the patient isn't eating,' which misses the cytokine-driven catabolism that is the actual mechanism. Build your mental model around mechanisms and tumor-specific associations, not just a list.

From real student decks
84%have cards covering this topic
54%have mature cards

Common misconceptions

Common mistake
Wrong: Small cell lung cancer causes hypercalcemia via PTHrP secretion.
Right: Small cell lung cancer causes SIADH (via ADH) and ectopic ACTH (Cushing syndrome), while squamous cell lung cancer causes hypercalcemia via PTHrP.
Small cell lung cancer is neuroendocrine in origin, which is why it secretes peptide hormones like ADH and ACTH — not PTHrP. Squamous cell lung carcinoma is the PTHrP producer, causing hypercalcemia. The key mental model: neuroendocrine → SIADH + Cushing; squamous → hypercalcemia. If you see a small cell vignette with high calcium, look for a second explanation (like bone mets), not PTHrP from the tumor itself.
Common mistake
Wrong: All malignancy-associated hypercalcemia is caused by PTHrP secretion.
Right: Malignancy-associated hypercalcemia can result from PTHrP (solid tumors), osteolytic bone metastases, or ectopic 1,25-(OH)2 vitamin D production (lymphomas).
PTHrP is just one of three ways malignancy raises calcium, and the exam will make you distinguish them. Osteolytic metastases (breast cancer, multiple myeloma) destroy bone directly via local cytokines like RANK-L — no circulating PTHrP involved. Lymphomas express 1-alpha-hydroxylase and overproduce calcitriol, raising calcium through gut absorption. When you see a lymphoma patient with hypercalcemia, think calcitriol; when you see myeloma, think bone destruction — not PTHrP.
Common mistake
Wrong: Cancer cachexia results solely from reduced caloric intake due to anorexia.
Right: Cancer cachexia is driven primarily by tumor-induced cytokines (TNF-α/cachectin, IL-1, IL-6, IFN-γ) that cause muscle proteolysis and lipolysis independent of caloric intake.
Cachexia is an active catabolic state, not just starvation. TNF-α (originally named cachectin for this reason), IL-1, IL-6, and IFN-γ are released by the tumor and host immune cells, driving muscle proteolysis and fat lipolysis even when caloric intake is adequate. This is why feeding a cachectic cancer patient more calories doesn't fully reverse the wasting — the cytokines are continuously breaking down tissue regardless. The exam tests this distinction when it asks about the mechanism, not just the clinical appearance.
Common mistake
Gap: Missing renal cell carcinoma as a high-yield source of multiple paraneoplastic syndromes including polycythemia
Renal cell carcinoma can secrete erythropoietin causing polycythemia, PTHrP causing hypercalcemia, and ACTH causing Cushing syndrome — making it a classic source of diverse paraneoplastic syndromes.
Renal cell carcinoma is one of the highest-yield multi-syndrome tumors on Step 1. It can secrete EPO (polycythemia), PTHrP (hypercalcemia), ACTH (Cushing syndrome), and renin (hypertension) — all paraneoplastic. When a vignette describes a patient with an incidental renal mass plus unexplained polycythemia or hypercalcemia without bone mets, think RCC producing ectopic hormone. This is distinct from the polycythemia of hepatocellular carcinoma or cerebellar hemangioblastoma, which also produce EPO ectopically.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Match specific paraneoplastic syndromes to lung cancer subtypes — especially knowing that small cell produces SIADH (ectopic ADH) and Cushing syndrome (ectopic ACTH), while squamous cell causes hypercalcemia via PTHrP, and large cell can cause gynecomastia via β-hCG.
  2. Identify paraneoplastic syndromes from non-lung malignancies — including renal cell carcinoma (EPO → polycythemia, PTHrP, ACTH), hepatocellular carcinoma (IGF-2 → hypoglycemia), thymoma (myasthenia gravis), and dermatomyositis or acanthosis nigricans as cutaneous markers of internal malignancy.
  3. Differentiate the three mechanisms of malignancy-associated hypercalcemia: PTHrP secretion by solid tumors (especially squamous cell lung and renal cell), direct osteolytic bone metastases (breast, myeloma), and ectopic 1,25-(OH)2 vitamin D production by lymphomas — and predict which applies given the clinical context.
  4. Explain cancer cachexia mechanistically — recognizing that it is driven by tumor-secreted cytokines (TNF-α/cachectin, IL-1, IL-6, IFN-γ) causing active muscle proteolysis and lipolysis, not simply reduced caloric intake from anorexia.

Can you avoid these mistakes?

A 58-year-old smoker presents with hyponatremia, urine osmolality > serum osmolality, and a hilar lung mass on CXR. Biopsy shows small blue cells. What is the paraneoplastic mechanism, and which other major paraneoplastic syndrome should you consider in this patient?
A patient with known multiple myeloma develops hypercalcemia. A second patient with squamous cell lung carcinoma also develops hypercalcemia. Are the mechanisms the same? Walk through the distinct pathophysiology for each.
A 65-year-old man with renal cell carcinoma has a hematocrit of 58% and no pulmonary pathology. What is the mechanism of his erythrocytosis, and what other paraneoplastic syndromes should you be able to list for this tumor type?
Your patient has advanced pancreatic cancer and has lost 20 lbs over 3 months despite eating 2000 calories/day. A medical student says the weight loss is because cancer patients don't feel like eating. What is the actual mechanism driving this patient's cachexia, and which cytokines are central to it?

Related topics

Benign vs Malignant Neoplasia Reversible vs Irreversible Cell Injury Types of Necrosis Apoptosis (Intrinsic and Extrinsic Pathways) Cell Adaptations (Atrophy, Hypertrophy, Hyperplasia, Metaplasia, Dysplasia)

See how your Anki deck covers this topic.

Upload your deck for a free audit →